{"transactions":[{"id":2117917,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":1,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":2,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2022-11-14T13:40:35.000Z","date":"2022-11-10","kind":"purchase","acquired":true,"shares":4000000,"price":5,"value":20000000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Dexcel Pharma Technologies Ltd. (\"Dexcel\") is the direct beneficial holder of 4,684,130 common shares. Dexxon Holding Ltd. (\"Dexxon\") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common shares were purchased by Dexcel in a registered public offering on November 10, 2022."}],"balance_after":102849443,"source":{"system":"sec-edgar","filing":"0001104659-22-117847","document":"tm2230168d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000110465922117847/tm2230168d1_4.xml","form_type":"4"}},{"id":2290276,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":1,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":2,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2022-04-26T10:48:12.000Z","date":"2022-04-25","kind":"purchase","acquired":true,"shares":8600,"price":3.9111,"value":33635.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Dexcel Pharma Technologies Ltd. (\"Dexcel\") is the direct beneficial holder of 684,130 common shares. Dexxon Holding Ltd. (\"Dexxon\") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is the weighted average price. The common shares were purchased in multiple transactions at prices ranging from $3.825 to $3.99."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Dexcel Pharma Technologies Ltd. (\"Dexcel\") is the direct beneficial holder of 684,130 common shares. Dexxon Holding Ltd. (\"Dexxon\") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity."}],"balance_after":98849443,"source":{"system":"sec-edgar","filing":"0001104659-22-049930","document":"tm2213532d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000110465922049930/tm2213532d1_4.xml","form_type":"4"}},{"id":2290275,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":1,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":2,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2022-04-26T10:48:12.000Z","date":"2022-04-22","kind":"purchase","acquired":true,"shares":31685,"price":3.8289,"value":121318.6965,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Dexcel Pharma Technologies Ltd. (\"Dexcel\") is the direct beneficial holder of 684,130 common shares. Dexxon Holding Ltd. (\"Dexxon\") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the weighted average price. The common shares were purchased in multiple transactions at prices ranging from $3.685 to $3.88."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Dexcel Pharma Technologies Ltd. (\"Dexcel\") is the direct beneficial holder of 684,130 common shares. Dexxon Holding Ltd. (\"Dexxon\") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity."}],"balance_after":98840843,"source":{"system":"sec-edgar","filing":"0001104659-22-049930","document":"tm2213532d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000110465922049930/tm2213532d1_4.xml","form_type":"4"}},{"id":3483657,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-06-19T18:24:24.000Z","date":"2019-06-19","kind":"purchase","acquired":true,"shares":4957,"price":8.1693,"value":40495.2201,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $8.00 to $8.27, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22860013,"source":{"system":"sec-edgar","filing":"0001144204-19-031542","document":"tv523822_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419031542/tv523822_4.xml","form_type":"4"}},{"id":3483656,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-06-19T18:24:24.000Z","date":"2019-06-18","kind":"purchase","acquired":true,"shares":6706,"price":8.2107,"value":55060.9542,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $8.09 to $8.29, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22855056,"source":{"system":"sec-edgar","filing":"0001144204-19-031542","document":"tv523822_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419031542/tv523822_4.xml","form_type":"4"}},{"id":3483655,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.000037453 par value per share","published_at":"2019-06-19T18:24:24.000Z","date":"2019-06-17","kind":"purchase","acquired":true,"shares":6541,"price":8.5346,"value":55824.8186,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $8.11 to $8.70, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22848350,"source":{"system":"sec-edgar","filing":"0001144204-19-031542","document":"tv523822_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419031542/tv523822_4.xml","form_type":"4"}},{"id":3489008,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-06-14T18:10:59.000Z","date":"2019-06-14","kind":"purchase","acquired":true,"shares":7144,"price":7.9107,"value":56514.0408,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.65 to $8.00, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22841809,"source":{"system":"sec-edgar","filing":"0001144204-19-031054","document":"tv523638_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419031054/tv523638_4.xml","form_type":"4"}},{"id":3489007,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-06-14T18:10:59.000Z","date":"2019-06-13","kind":"purchase","acquired":true,"shares":7367,"price":7.9466,"value":58542.6022,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.67 to $8.39, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22834665,"source":{"system":"sec-edgar","filing":"0001144204-19-031054","document":"tv523638_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419031054/tv523638_4.xml","form_type":"4"}},{"id":3489006,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.000037453 par value per share","published_at":"2019-06-14T18:10:59.000Z","date":"2019-06-12","kind":"purchase","acquired":true,"shares":7500,"price":8.2992,"value":62244.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $8.16 to $8.77, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22827298,"source":{"system":"sec-edgar","filing":"0001144204-19-031054","document":"tv523638_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419031054/tv523638_4.xml","form_type":"4"}},{"id":3493704,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-06-11T18:19:10.000Z","date":"2019-06-11","kind":"purchase","acquired":true,"shares":7189,"price":8.5817,"value":61693.8413,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $8.41 to $8.75, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22819798,"source":{"system":"sec-edgar","filing":"0001144204-19-030612","document":"tv523411_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419030612/tv523411_4.xml","form_type":"4"}},{"id":3493703,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-06-11T18:19:10.000Z","date":"2019-06-10","kind":"purchase","acquired":true,"shares":7500,"price":8.3459,"value":62594.25,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.89 to $8.68, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22812609,"source":{"system":"sec-edgar","filing":"0001144204-19-030612","document":"tv523411_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419030612/tv523411_4.xml","form_type":"4"}},{"id":3493702,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.000037453 par value per share","published_at":"2019-06-11T18:19:10.000Z","date":"2019-06-07","kind":"purchase","acquired":true,"shares":6649,"price":7.965,"value":52959.285,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.73 to $8.10, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22805109,"source":{"system":"sec-edgar","filing":"0001144204-19-030612","document":"tv523411_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419030612/tv523411_4.xml","form_type":"4"}},{"id":3498329,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.000017727 par value per share","published_at":"2019-06-06T18:29:07.000Z","date":"2019-06-04","kind":"purchase","acquired":true,"shares":2424242,"price":8.25,"value":19999996.5,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Myovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":40765599,"source":{"system":"sec-edgar","filing":"0001144204-19-030140","document":"tv523092_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419030140/tv523092_4.xml","form_type":"4"}},{"id":3498321,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-06-06T18:25:25.000Z","date":"2019-06-06","kind":"purchase","acquired":true,"shares":7082,"price":7.9951,"value":56621.2982,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.73 to $8.57, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22798460,"source":{"system":"sec-edgar","filing":"0001144204-19-030138","document":"tv523225_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419030138/tv523225_4.xml","form_type":"4"}},{"id":3498320,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-06-06T18:25:25.000Z","date":"2019-06-05","kind":"purchase","acquired":true,"shares":6540,"price":8.015,"value":52418.1,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.68 to $8.33, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22791378,"source":{"system":"sec-edgar","filing":"0001144204-19-030138","document":"tv523225_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419030138/tv523225_4.xml","form_type":"4"}},{"id":3498319,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.000037453 par value per share","published_at":"2019-06-06T18:25:25.000Z","date":"2019-06-04","kind":"purchase","acquired":true,"shares":7500,"price":7.5881,"value":56910.75,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.42 to $7.71, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22784838,"source":{"system":"sec-edgar","filing":"0001144204-19-030138","document":"tv523225_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419030138/tv523225_4.xml","form_type":"4"}},{"id":3504238,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-06-03T18:33:31.000Z","date":"2019-06-03","kind":"purchase","acquired":true,"shares":5424,"price":7.7092,"value":41814.7008,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.64 to $7.74, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22777338,"source":{"system":"sec-edgar","filing":"0001144204-19-029540","document":"tv522951_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419029540/tv522951_4.xml","form_type":"4"}},{"id":3504237,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-06-03T18:33:31.000Z","date":"2019-05-31","kind":"purchase","acquired":true,"shares":5071,"price":7.6991,"value":39042.1361,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.41 to $7.84, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22771914,"source":{"system":"sec-edgar","filing":"0001144204-19-029540","document":"tv522951_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419029540/tv522951_4.xml","form_type":"4"}},{"id":3504236,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-06-03T18:33:31.000Z","date":"2019-05-30","kind":"purchase","acquired":true,"shares":300,"price":8.9066,"value":2671.98,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $8.71 to $9.03, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22766843,"source":{"system":"sec-edgar","filing":"0001144204-19-029540","document":"tv522951_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419029540/tv522951_4.xml","form_type":"4"}},{"id":3504235,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.000037453 par value per share","published_at":"2019-06-03T18:33:31.000Z","date":"2019-05-30","kind":"purchase","acquired":true,"shares":6951,"price":7.9726,"value":55417.5426,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.70 to $8.70, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22766543,"source":{"system":"sec-edgar","filing":"0001144204-19-029540","document":"tv522951_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419029540/tv522951_4.xml","form_type":"4"}},{"id":3508306,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-05-29T18:28:04.000Z","date":"2019-05-29","kind":"purchase","acquired":true,"shares":6882,"price":7.5535,"value":51983.187,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.40 to $7.69, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22759592,"source":{"system":"sec-edgar","filing":"0001144204-19-028688","document":"tv522616_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419028688/tv522616_4.xml","form_type":"4"}},{"id":3508305,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-05-29T18:28:04.000Z","date":"2019-05-28","kind":"purchase","acquired":true,"shares":3807,"price":7.6818,"value":29244.6126,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.65 to $7.70, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22752710,"source":{"system":"sec-edgar","filing":"0001144204-19-028688","document":"tv522616_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419028688/tv522616_4.xml","form_type":"4"}},{"id":3508304,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.000037453 par value per share","published_at":"2019-05-29T18:28:04.000Z","date":"2019-05-24","kind":"purchase","acquired":true,"shares":3796,"price":7.7011,"value":29233.3756,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases were made by Roivant and not the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.66 to $7.74, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22748903,"source":{"system":"sec-edgar","filing":"0001144204-19-028688","document":"tv522616_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419028688/tv522616_4.xml","form_type":"4"}},{"id":3509798,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-05-28T16:41:48.000Z","date":"2019-05-23","kind":"purchase","acquired":true,"shares":4802,"price":7.7576,"value":37251.9952,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F6","text":"The transaction was a series of open market purchases made under a trading plan established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.645 to $7.98, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22745107,"source":{"system":"sec-edgar","filing":"0001144204-19-028456","document":"tv522522_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419028456/tv522522_4.xml","form_type":"4"}},{"id":3509797,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.000037453 par value per share","published_at":"2019-05-28T16:41:48.000Z","date":"2019-05-22","kind":"purchase","acquired":true,"shares":5033,"price":8.0584,"value":40557.9272,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.825 to $8.43, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22740305,"source":{"system":"sec-edgar","filing":"0001144204-19-028456","document":"tv522522_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419028456/tv522522_4.xml","form_type":"4"}},{"id":3512986,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.000037453 par value per share","published_at":"2019-05-23T17:04:03.000Z","date":"2019-05-21","kind":"purchase","acquired":true,"shares":9995,"price":8.5151,"value":85108.4245,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $8.31 to $8.69, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22735272,"source":{"system":"sec-edgar","filing":"0001144204-19-027995","document":"tv522327_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419027995/tv522327_4.xml","form_type":"4"}},{"id":3514623,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-05-22T16:21:35.000Z","date":"2019-05-20","kind":"purchase","acquired":true,"shares":1715,"price":8.3867,"value":14383.1905,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $8.36 to $8.47, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22725277,"source":{"system":"sec-edgar","filing":"0001144204-19-027731","document":"tv522008_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419027731/tv522008_4.xml","form_type":"4"}},{"id":3514622,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.000037453 par value per share","published_at":"2019-05-22T16:21:35.000Z","date":"2019-05-20","kind":"purchase","acquired":true,"shares":8285,"price":7.9833,"value":66141.6405,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.35 to $8.35, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22723562,"source":{"system":"sec-edgar","filing":"0001144204-19-027731","document":"tv522008_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419027731/tv522008_4.xml","form_type":"4"}},{"id":3517989,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-05-20T16:21:38.000Z","date":"2019-05-17","kind":"purchase","acquired":true,"shares":6200,"price":7.3615,"value":45641.3,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $7.03 - $7.85, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22715277,"source":{"system":"sec-edgar","filing":"0001144204-19-027306","document":"tv522005_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419027306/tv522005_4.xml","form_type":"4"}},{"id":3517988,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.000037453 par value per share","published_at":"2019-05-20T16:21:38.000Z","date":"2019-05-16","kind":"purchase","acquired":true,"shares":5408,"price":6.7896,"value":36718.1568,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Roivant informed the Reporting Persons that the transaction was a series of open market purchases in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is the weighted average price. Roivant informed the Reporting Persons that the Common Shares were purchased in multiple transactions at prices ranging from $6.70 to $6.93, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22709077,"source":{"system":"sec-edgar","filing":"0001144204-19-027306","document":"tv522005_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420419027306/tv522005_4.xml","form_type":"4"}},{"id":3585615,"issuer":{"id":130622,"kind":"organization","name":"Sio Gene Therapies Inc.","symbol":"SIOX"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.00001 par value per share","published_at":"2019-03-19T17:04:22.000Z","date":"2019-03-18","kind":"purchase","acquired":true,"shares":6666667,"price":1.5,"value":10000000.5,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Axovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":105952381,"source":{"system":"sec-edgar","filing":"0001144204-19-014887","document":"tv516472_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636050/000114420419014887/tv516472_4.xml","form_type":"4"}},{"id":3723100,"issuer":{"id":130622,"kind":"organization","name":"Sio Gene Therapies Inc.","symbol":"SIOX"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.00001 par value per share","published_at":"2018-12-20T07:29:23.000Z","date":"2018-12-18","kind":"purchase","acquired":true,"shares":10000000,"price":1,"value":10000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Axovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":99285714,"source":{"system":"sec-edgar","filing":"0001144204-18-065508","document":"tv509477_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636050/000114420418065508/tv509477_form4.xml","form_type":"4"}},{"id":3797784,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.000037453 par value per share","published_at":"2018-10-03T17:58:08.000Z","date":"2018-10-01","kind":"purchase","acquired":true,"shares":2678571,"price":14,"value":37499994.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Urovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":22703669,"source":{"system":"sec-edgar","filing":"0001144204-18-052388","document":"tv504072_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420418052388/tv504072_4.xml","form_type":"4"}},{"id":3901190,"issuer":{"id":130622,"kind":"organization","name":"Sio Gene Therapies Inc.","symbol":"SIOX"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.00001 par value per share","published_at":"2018-06-07T08:43:13.000Z","date":"2018-06-05","kind":"purchase","acquired":true,"shares":14285714,"price":1.75,"value":24999999.5,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Axovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":89285714,"source":{"system":"sec-edgar","filing":"0001144204-18-033168","document":"tv495927_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636050/000114420418033168/tv495927_4.xml","form_type":"4"}},{"id":3969011,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.000017727 par value per share","published_at":"2018-04-04T19:18:40.000Z","date":"2018-04-02","kind":"purchase","acquired":true,"shares":1110015,"price":20.27,"value":22500004.05,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the \"Common Shares\") of Myovant Sciences Ltd. held by Roivant Sciences Ltd. (\"Roivant\"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":38341357,"source":{"system":"sec-edgar","filing":"0001144204-18-019287","document":"tv490385_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636684/000114420418019287/tv490385_4.xml","form_type":"4"}},{"id":4099323,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Participating Convertible Preferred Shares","published_at":"2018-01-16T13:56:27.000Z","date":"2018-01-12","kind":"purchase","acquired":true,"shares":664000,"price":100,"value":66400000.0,"ownership":{"direct":false,"nature":"See footnotes 3 and 4"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"shares","element":"transactionShares","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the Preferred Shares held by Roivant. Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Preferred Shares."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Preferred Shares owned directly by Roivant. The Reporting Persons do not directly own any Preferred Shares. The Reporting Persons disclaim beneficial ownership of the Preferred Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":1164000,"derivative":{"exercise_price":7.13,"expiration_date":"2021-10-16","underlying":"Common shares, no par value","underlying_shares":13025536},"source":{"system":"sec-edgar","filing":"0001144204-18-002187","document":"tv476968_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000114420418002187/tv476968_4.xml","form_type":"4"}},{"id":4183853,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":122425,"kind":"organization","name":"Dexxon Holdings Ltd.","position":1,"cik":"0001636684","reported_name":"Dexxon Holdings Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":2,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":3,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Participating Convertible Preferred Shares","published_at":"2017-10-18T16:48:32.000Z","date":"2017-10-16","kind":"purchase","acquired":true,"shares":500000,"price":100,"value":50000000.0,"ownership":{"direct":false,"nature":"See footnotes 3 and 4"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"shares","element":"transactionShares","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Dexxon Holdings Ltd. (\"Dexxon\"), Dexcel Pharma Technologies Ltd. (\"DPT\") and Dan Oren (together with Dexxon and DPT the \"Reporting Persons\") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the Preferred Shares held by Roivant. Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Preferred Shares."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Preferred Shares owned directly by Roivant. The Reporting Persons do not directly own any Preferred Shares. The Reporting Persons disclaim beneficial ownership of the Preferred Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise."}],"balance_after":500000,"derivative":{"exercise_price":7.13,"expiration_date":"2021-10-16","underlying":"Common shares, no par value","underlying_shares":9808386},"source":{"system":"sec-edgar","filing":"0001144204-17-052970","document":"tv476968_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000114420417052970/tv476968_4.xml","form_type":"4"}}]}